Vyome Holdings, Inc. Net Assets
Vyome Holdings, Inc. net assets. Based on the latest financial reports, Vyome Holdings, Inc. (HIND) has net assets worth $7.31 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.18 Million) and total liabilities ($1.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Vyome Holdings, Inc. to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.31 Million |
| % of Total Assets | 79.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | -91.51% |
| 10-Year Change | 28.0% |
| Growth Volatility | 627.9 |
Net Assets of Vyome Holdings, Inc. (2003–2025)
Net assets of Vyome Holdings, Inc. from 2003 to 2025. This chart illustrates how Vyome Holdings, Inc.'s net assets have evolved over time, based on quarterly financial data. See HIND equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Vyome Holdings, Inc. (2003–2025)
The table below shows the annual net assets of Vyome Holdings, Inc. from 2003 to 2025. For live market cap and overall valuation, see Vyome Holdings, Inc. (HIND) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.76 Million | +1586.96% |
| 2024-12-31 | $-253.00K | -103.80% |
| 2023-12-31 | $6.66 Million | +82.00% |
| 2022-12-31 | $3.66 Million | -91.74% |
| 2021-12-31 | $44.33 Million | +206.00% |
| 2020-12-31 | $14.49 Million | -39.90% |
| 2019-12-31 | $24.11 Million | -23.86% |
| 2018-12-31 | $31.66 Million | -58.54% |
| 2017-12-31 | $76.37 Million | +2498.40% |
| 2016-12-31 | $2.94 Million | -19.98% |
| 2015-12-31 | $3.67 Million | -44.88% |
| 2014-12-31 | $6.66 Million | -54.60% |
| 2013-12-31 | $14.68 Million | +23.61% |
| 2012-12-31 | $11.88 Million | -40.75% |
| 2011-12-31 | $20.04 Million | -32.54% |
| 2010-12-31 | $29.71 Million | +432.29% |
| 2009-12-31 | $5.58 Million | -51.07% |
| 2008-12-31 | $11.41 Million | -74.81% |
| 2007-12-31 | $45.28 Million | +58.47% |
| 2006-12-31 | $28.57 Million | +1347.10% |
| 2005-12-31 | $1.97 Million | +394.71% |
| 2003-12-31 | $-670.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vyome Holdings, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8505957500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Vyome Holdings, Inc. Net Assets Breakdown (December 2025)
Vyome Holdings, Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.92K | 0.24% |
| Other Comprehensive Income | $-78.86K | -3.23% |
| Other Components | $90.08 Million | 3688.63% |
| Total Equity | $2.44 Million | 100.00% |
Vyome Holdings, Inc. Competitors by Market Cap
The table below lists competitors of Vyome Holdings, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tellusgruppen AB
ST:TELLUS
|
$12.43 Million |
|
Telefast Indonesia
JK:TFAS
|
$12.43 Million |
|
Playtech Plc
LSE:PTEC
|
$12.43 Million |
|
Avillion Bhd
KLSE:8885
|
$12.45 Million |
|
TRIBECA RESOURCES CORPORA
F:381
|
$12.42 Million |
|
Cannabist Company Holdings Inc
NEO:CBST
|
$12.41 Million |
|
Metal Energy Corp
V:MERG
|
$12.41 Million |
|
GMV Minerals Inc
V:GMV
|
$12.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vyome Holdings, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -253,000 to 2,442,059, a change of 2,695,059.
- Net loss of 10,262,007 reduced equity.
- New share issuances of 7,857,714 increased equity.
- Other comprehensive income increased equity by 25,136.
- Other factors increased equity by 5,074,216.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.26 Million | -420.22% |
| Share Issuances | $7.86 Million | +321.77% |
| Other Comprehensive Income | $25.14K | +1.03% |
| Other Changes | $5.07 Million | +207.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Vyome Holdings, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $-12219.59 | $1.77 | x |
| 2005-12-31 | $14716.79 | $1.77 | x |
| 2006-12-31 | $160139.95 | $1.77 | x |
| 2007-12-31 | $53708.36 | $1.77 | x |
| 2008-12-31 | $1964.58 | $1.77 | x |
| 2009-12-31 | $3253.70 | $1.77 | x |
| 2010-12-31 | $10232.18 | $1.77 | x |
| 2011-12-31 | $1924.11 | $1.77 | x |
| 2012-12-31 | $871.03 | $1.77 | x |
| 2014-12-31 | $867708.33 | $1.77 | x |
| 2015-12-31 | $478255.21 | $1.77 | x |
| 2017-12-31 | $9930689.21 | $1.77 | x |
| 2018-12-31 | $3618564.34 | $1.77 | x |
| 2019-12-31 | $1114001.85 | $1.77 | x |
| 2020-12-31 | $336930.23 | $1.77 | x |
| 2021-12-31 | $294187.13 | $1.77 | x |
| 2022-12-31 | $12508.54 | $1.77 | x |
| 2023-12-31 | $1622.35 | $1.77 | x |
| 2024-12-31 | $-12.27 | $1.77 | x |
| 2025-12-31 | $1.13 | $1.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vyome Holdings, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -420.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3209.75%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 2.66x
- Recent ROE (-420.22%) is below the historical average (-308.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.83 Million |
| 2005 | -567.99% | 0.00% | 0.00x | 5.85x | $-11.41 Million |
| 2006 | -61.91% | 0.00% | 0.00x | 1.26x | $-20.55 Million |
| 2007 | -63.11% | 0.00% | 0.00x | 1.30x | $-33.10 Million |
| 2008 | -332.08% | 0.00% | 0.00x | 2.48x | $-39.01 Million |
| 2009 | -572.10% | 0.00% | 0.00x | 2.91x | $-32.49 Million |
| 2010 | -58.39% | 0.00% | 0.00x | 1.30x | $-20.32 Million |
| 2011 | -129.72% | 0.00% | 0.00x | 1.62x | $-28.00 Million |
| 2012 | -197.56% | -7519.23% | 0.01x | 2.20x | $-24.65 Million |
| 2013 | -175.63% | 0.00% | 0.00x | 1.80x | $-27.25 Million |
| 2014 | -392.09% | 0.00% | 0.00x | 2.16x | $-26.80 Million |
| 2015 | -694.23% | -8732.53% | 0.03x | 3.15x | $-25.87 Million |
| 2016 | -794.86% | -2969.62% | 0.11x | 2.40x | $-23.65 Million |
| 2017 | -44.28% | -2627.34% | 0.01x | 1.16x | $-41.45 Million |
| 2018 | -256.30% | -13375.68% | 0.01x | 1.46x | $-84.32 Million |
| 2019 | -307.82% | -491.80% | 0.38x | 1.64x | $-76.62 Million |
| 2020 | -149.30% | -191.43% | 0.28x | 2.74x | $-23.08 Million |
| 2021 | -142.43% | -464.31% | 0.26x | 1.18x | $-67.58 Million |
| 2022 | -1262.33% | -411.16% | 1.00x | 3.08x | $-46.58 Million |
| 2023 | -170.90% | -131.22% | 0.81x | 1.61x | $-12.05 Million |
| 2024 | 0.00% | -89.06% | 1.67x | 0.00x | $-7.10 Million |
| 2025 | -420.22% | -3209.75% | 0.05x | 2.66x | $-10.51 Million |
Industry Comparison
This section compares Vyome Holdings, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vyome Holdings, Inc. (HIND) | $7.31 Million | 0.00% | 0.26x | $12.42 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinica… Read more